VÝVGART[®] Hytrulo

(efgartigimod alfa and hyaluronidase-qvfc)

Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

CIDP Doctor Discussion Guide

CIDP affects everyone differently and can change over time. It's important that your doctor knows how the condition is impacting your daily activities. Use this guide to help you discuss your symptoms and abilities.

There are questions within this guide that can help you partner with your doctor and get the most out of your conversations, including if VYVGART Hytrulo could be right for you.

Take a look and get started

What is VYVGART[®] HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

SELECT IMPORTANT SAFETY INFORMATION

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information on page 4. Please see the full Prescribing Information for <u>VYVGART Hytrulo</u>.

How are your CIDP symptoms affecting you?

VÝVGART[®] Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

Instructions: During your next appointment, your doctor may ask you questions about your CIDP symptoms. Consider how your symptoms affect your everyday life. Circle the figure below in the places where you experience symptoms. Then, use the lines provided to describe your symptoms and how they are impacting your life.

Today's date:	Last treatment	date:
Arms Example Symptom(s): Weakness Impact: Difficult to wash my hair		Hands Example Symptom(s): Numbness Impact: Hard to button a shirt
Symptom(s):		Symptom(s):
Impact:		Impact:
Legs Example Symptom(s): Loss of balance and trouble walking Impact: Difficult to do activities like grocery shopping		Feet Example Symptom(s): Foot drop (ankle weakness) Impact: Challenging to go up and down the stairs without holding onto the railing
Symptom(s):		Symptom(s):
Impact:		Impact:
Do you use a mobility device?	If yes, list which type(s): _	
Have you had any falls related to y	our CIDP symptoms since your	last doctor visit?

Please see Important Safety Information on page 4. Please see the full Prescribing Information for <u>VYVGART Hytrulo</u>.

Reflect on your CIDP treatment

It can be helpful to regularly ask yourself questions about your current CIDP treatment. Respond to the questions below to get a better understanding of how well it's working for you.

If you're not currently on treatment, skip this page.

How often are you able to do the daily activities that are important to you? Most of the time Sometimes Not often Not at a Most of the time Sometimes Most of the time Sometimes Not often Not at a Most of the time Sometimes Not often Not at a How often is your schedule impacted by your CIDP treatment?	Are your symptoms	s being managed w	vell?	
to you? Most of the time Sometimes Not often Not at a Most of the time Sometimes Not often Not at a How often is your schedule impacted by your CIDP treatment?	Most of the time	Sometimes	Not often	📃 Not at a
How often do treatment side effects affect you daily? Most of the time Sometimes Not often Not at a How often is your schedule impacted by your CIDP treatment?	÷	able to do the daily	activities that a	re important
Most of the time Sometimes Not often Not at a	Most of the time	Sometimes	Not often	🗌 Not at a
How often is your schedule impacted by your CIDP treatment?	How often do treat	ment side effects a	offect you daily?	
	Most of the time	Sometimes	Not often	🗌 Not at a
	How often is your s	chedule impacted	by your CIDP tr	eatment?
	Most of the time	Sometimes	Not often	Not at a
	Most of the time			🗌 Not at a
				🗌 Not at a
				Not at a
				Not at a
				Not at a

CIDP=chronic inflammatory demyelinating polyneuropathy

Please see Important Safety Information on page 4. Please see the full Prescribing Information for <u>VYVGART Hytrulo</u>.

IMPORTANT SAFETY INFORMATION

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

- Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/ or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
- Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

Infusion-Related Reactions.

VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidaseqvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

<u>Please see the full Prescribing</u> <u>Information for VYVGART HYTRULO</u> <u>and talk to your doctor.</u>

Talk to your doctor to see if **VYVGART Hytrulo is right for you**

ÝVGART[®] Hytrulo (efgartigimod alfa and hyaluronidase-gvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

A different approach to CIDP

The first innovation in CIDP treatment in over 30 years

The first and only plasma-free treatment approved by the FDA for adults with CIDP

One weekly injection, given under the skin by a healthcare professional, that takes ~30 to 90 seconds*

*After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.

CIDP=chronic inflammatory demyelinating polyneuropathy

Bring this guide to your next appointment to start the conversation Learn more at VYVGARTHytruloCIDP.com



Information for your doctor

Learn about the safety and efficacy of VYVGART Hytrulo on a site for healthcare professionals: VYVGARTHCP.com

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO may cause serious side effects, including infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/ sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

Please see Important Safety Information on page 4. Please see the full Prescribing Information for VYVGART Hytrulo.

VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx. For U.S. audiences only. ©2024 argenx US-VYV_HYT-24-00035 V1 09/2024

